Abbott
Abbott Laboratories, commonly known as Abbott, is a leading global healthcare company headquartered in the United States. Founded in 1888, Abbott has established a strong presence in various operational regions, including North America, Europe, and Asia. The company operates primarily in the medical devices, diagnostics, nutrition, and pharmaceuticals sectors. Abbott is renowned for its innovative products, such as the FreeStyle Libre glucose monitoring system and Similac infant formula, which set industry standards for quality and effectiveness. With a commitment to advancing health and well-being, Abbott has achieved significant milestones, including the rapid development of COVID-19 testing solutions. As a market leader, Abbott consistently ranks among the top healthcare companies worldwide, recognised for its dedication to research and development, and its ability to deliver cutting-edge solutions that improve patient outcomes.
DitchCarbon Score
How does Abbott's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbott's score of 57 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abbott's reported carbon emissions
In 2023, Abbott reported total carbon emissions of approximately 917,000,000 kg CO2e, comprising 510,000,000 kg CO2e from Scope 1 and 407,000,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets under its 2030 Sustainability Plan, aiming to reduce absolute Scope 1 and 2 emissions by 30% from a 2018 baseline by the year 2030. This commitment aligns with the Science Based Targets initiative (SBTi), which also includes a goal for 82% of its suppliers to have science-based targets by 2026. Abbott is also committed to achieving net-zero emissions across all scopes by 2050. The company’s emissions reduction strategy is designed to address both direct and indirect emissions, reflecting a comprehensive approach to sustainability in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 620,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 648,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbott is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
